Chronic illness drug developer Sigilon Therapeutics has filed to go public after raising almost $200m from investors including Eli Lilly.

Sigilon Therapeutics, a US-based chronic illness therapy developer backed by pharmaceutical firm Eli Lilly, has filed for a $100m initial public offering on the Nasdaq Global Market. Founded in 2015, Sigilon has built a drug development platform dubbed Shielded Living Therapeutics which it is using to create therapeutic molecules that can make up for proteins, antibodies…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.